期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

成纤维细胞生长因子23与血液透析患者钙、磷代谢紊乱的研究进展 被引量：2

下载PDF
导出
摘要 慢性肾衰竭患者存在钙、磷代谢紊乱，既往的研究多集中在甲状旁腺激素-维生素D轴对血磷、钙、甲状旁腺激素（PTH）的调节作用，近来发现骨骼作为一个内分泌器官产生的成纤维细胞生长因子23（Fibroblast growth factors 23，FGF23）作用于肾脏调节钙、磷代谢，由此形成的骨-肾激素轴发挥不同于甲状旁腺激素-维生素D轴的调节磷、维生素D平衡的重要作用。
作者 王莉 丁涵露
机构地区 四川省医学科学院四川省人民医院肾脏科
出处 《中国血液净化》 2009年第10期526-528,共3页 Chinese Journal of Blood Purification
关键词 成纤维细胞生长因子23 磷代谢紊乱 血液透析患者 甲状旁腺激素 慢性肾衰竭患者 钙 维生素D 内分泌器官
分类号 R591.44 [医药卫生—内科学] R581.1 [医药卫生—内分泌]
  • 相关文献

参考文献43

  • 1Yamashita T, YoshiokaM, Itoh N: Identification of a novel broblast growth factor, FGF-23, preferentially expressed in the entrolateral thalamic nucleus of the brain[J]. Biochem Biophys Res Commun, 2000, 277:494-498.
  • 2The HYP Consortium: A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets[J]. Nat Genet 1995,11:130-136.
  • 3Mirams M, Robinson BG, Mason RS, et al. Bone as a source of FGF23: regulation by phosphate[J]? Bone, 2004, 35: 1192-1199.
  • 4Liu S, Zhou J, Tang W, et al. Pathogenic role of Fgf23 in Hyp mice[J]. Am J hysiol Endocrinol Metab, 2006, 291: E38- E49.
  • 5Sitara D, RazzaqueMS, Hesse M et al. Homozygous ablation of fibroblast rowth factor-23 results in hyperphosphatemia and impaired keletogenesis, and reverses hypophosphatemia in Phex-deficient mice[J].Matrix Biol, 2004, 23:421 432.
  • 6Liu S, Zhon J, Tang W, et al. Pathogenic role of FGF23 in Hyp mice[J]. Am J Physiol Endocrinol Metab, 2006, 291: E38-E49.
  • 7Sitara D, RazzaqueMS, Hesse M, et al. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeleto-genesis, and reverses hypophosphatemia in Phex-deficient mice[J].Matrix Biol, 2004, 23:421-432.
  • 8Gupta A, Wirier K, Econs MJ, et al. FGF-23 is elevated by chronic hyperphosphatemia[J]. J Clin Endoerinol Metab, 2004, 89: 4489-4492.
  • 9Kolek OI, Hines ER, Jones MD, et al. lalpha, 25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renalgastrointestinal-skeletal axis that controls phosphate transport[J]. Am J-Physiol Gastrointest Liver Physiol, 2005,289: G1036-G1042.
  • 10hntoniucci DM, Yamashita T, Portale AA. Dietary phosphorus regulates serum fibroblast growth factor 23 concentrations in healthy men[J]. J Clin Endocrinol Netab, 2006, 91: 3144-3149.

同被引文献25

  • 1张春凤.中药灌肠治疗慢性肾功能衰竭湿浊证60例临床总结[J].吉林中医药,2006,26(2):21-21. 被引量：4
  • 2王英,王梅.终末期肾病患者钙磷代谢异常与血管钙化[J].中国血液净化,2006,5(3):152-155. 被引量：13
  • 3Moe S,Drueke T,Cunningham J,et al.Definition,evaluation,and classification of renal osteodystrophy:A position statement from Kidney Disease:Improving Global Outcomes (KDIGO)[J].Kidney Int,2006,69:1945-1953.
  • 4Henandez JD,Weaseling K,Salusky B.Role of parathyroid hormone and therapy with active vitamin D sterols in renal osteodystrophy[J].SeminDial,2005,18:290-295.
  • 5Goodman WG,Goldin J,Kuizon BD,et al.Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis[J].N Engl J Med,2000,342:1478-1483.
  • 6Block GA,Raggi P,Bellasi A,Kooienga L,Spiegel DM.Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients[J].Kidney Int,2007,71:438-441.
  • 7Suki WN,Zabaneh R,Cangiano JL,et al.Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients[J].Kidney Int,2007,72:1130-1137.
  • 8Curran MP,Robinson DM.Lanthanum carbonate:a review of its use in lowering serum phosphate in patients with end-stage renal disease[J].Drugs,2009;69(16):2329-49.
  • 9Liu S,Quarles ID.How fibroblast growth factor 23 works[J].J Am Soc Nephr ol,2007,18:1637-1647.
  • 10Tentori F,Hunt WC,Stidley CA,et al.Mortality risk among hemodialysis patients receiving different vitamin D analogs[J].Kidney Int,2006,70:1858-1865.

引证文献2

二级引证文献10

中国血液净化
2009年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部